Valuation: Charles River Laboratories International, Inc.

Market Cap 10.8B 9.5B 8.84B 8.12B 15.25B 1,036B 15.45B 105B 41.04B 512B 40.56B 39.68B 1,768B P/E 2026 *
36.6x
P/E 2027 * 24.5x
Enterprise Value 12.62B 11.09B 10.33B 9.48B 17.81B 1,210B 18.04B 123B 47.93B 597B 47.37B 46.34B 2,065B EV / Sales 2026 *
3.28x
EV / Sales 2027 * 3.11x
Free-Float
97%
Yield 2026 *
-
Yield 2027 * -
07-20 Analyst recommendations: Global Payments, Charles Schwab, US Bancorp, Datadog, Netflix… Zonebourse
07-13 BofA Adjusts Price Target on Charles River Laboratories International to $264 From $220 MT
07-13 Baird Adjusts Charles River Laboratories International Price Target to $255 From $213, Maintains Outperform Rating MT
07-13 Charles River Laboratories to Provide Cell Sequencing Services to Arovella Therapeutics MT
07-13 Charles River Provides Ngs Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches CI
07-13 Mizuho Adjusts Price Target on Charles River Laboratories International to $230 From $192, Maintains Neutral Rating MT
07-09 Morgan Stanley Adjusts Price Target on Charles River Laboratories International to $260 From $220 MT
07-07 Evercore ISI Adjusts Price Target on Charles River Laboratories International to $260 From $220 MT
07-02 Charles River Laboratories International Insider Sold Shares Worth $16,875,000, According to a Recent SEC Filing MT
07-01 Argus Raises Price Target on Charles River Laboratories International to $250 From $200, Maintains Buy Rating MT
06-18 Charles River Laboratories International, Inc. and Eli Lilly and Company Enter Collaboration to Optimize Ai/Ml Platform Through Nonclinical Testing Expertise CI
06-18 Rothschild & Co Redburn Adjusts Charles River Laboratories International PT to $241 From $230, Maintains Buy Rating MT
06-17 Charles River Laboratories Shares Rise After Morgan Stanley Upgrade MT
1 day-1.01%
1 week+4.62%
Current month+0.86%
1 month+8.02%
1 week 178.99
Extreme 178.9935
186.14
1 month 176.12
Extreme 176.122
189.52
Current year 146.62
Extreme 146.619
189.52
1 year 146.62
Extreme 146.619
189.52
3 years 146.62
Extreme 146.619
189.52
5 years 146.62
Extreme 146.619
189.52
10 years 146.62
Extreme 146.619
189.52
Manager TitleAgeSince
Chief Executive Officer 56 05/05/2026
Director of Finance/CFO 58 06/04/2026
Chief Tech/Sci/R&D Officer 45 12/01/2026
Director TitleAgeSince
Chairman 75 01/01/2000
Director/Board Member 56 05/05/2026
Chairman 69 05/05/2026
Change 5-day change 1-year change 3-year change Capi.($)
-1.01%+4.62% - - 10.8B
+0.98%+0.43%+0.21%+12.25% 47.74B
-2.79%+0.68%+395.28%+617.78% 39.98B
+0.99%+3.28%+11.76%+46.20% 36.23B
+14.37%+20.72%+23.08%+7.63% 35.59B
+0.62%+3.53%+5.41%+42.19% 27.91B
-1.97%-2.60% - - 16.71B
+0.80%+12.66%+32.21%+135.06% 16.45B
+2.36%-1.67%+4.71%+9.92% 13.21B
+7.84%+10.25%-3.14%-27.14% 12.93B
Average +2.28%+2.77%+58.69%+105.48% 27.42B
Weighted average by Cap. +2.39%+2.94%+77.22%+132.19%

Financials

2026 *2027 *
Net sales 3.85B 3.38B 3.15B 2.89B 5.43B 369B 5.5B 37.43B 14.62B 182B 14.45B 14.13B 630B 3.92B 3.45B 3.21B 2.95B 5.54B 376B 5.61B 38.16B 14.9B 186B 14.73B 14.41B 642B
Net income 285M 251M 233M 214M 402M 27.34B 408M 2.77B 1.08B 13.5B 1.07B 1.05B 46.67B 417M 367M 342M 314M 589M 40.02B 597M 4.06B 1.59B 19.76B 1.57B 1.53B 68.3B
Net Debt 1.81B 1.59B 1.48B 1.36B 2.56B 174B 2.59B 17.64B 6.89B 85.88B 6.81B 6.66B 297B 1.39B 1.22B 1.13B 1.04B 1.95B 133B 1.98B 13.47B 5.26B 65.59B 5.2B 5.09B 227B
Logo Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (59.8%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (21.1%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (19.1%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (80.9%) and sales of products (19.1%). Net sales are distributed geographically as follows: the United States (53.3%), Europe (27.5%), Canada (12.5%), Asia/Pacific (5.1%), and other (1.6%).
Employees
19,000
Date Price Change
27/07/26 CHF 184.25 -1.01%
24/07/26 CHF 186.14 +0.96%
23/07/26 CHF 184.36 +3.00%
22/07/26 CHF 178.99 -0.41%
21/07/26 CHF 179.74 +2.05%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
224.30USD
Average target price
230.93USD
Spread / Average Target
+2.96%

Quarterly revenue - Rate of surprise